

**Verici Dx plc**  
**("Verici Dx" or the "Company")**

**Statement re. Silicon Valley Bank**

Verici Dx plc (AIM: VRCI), a developer of advanced clinical diagnostics for organ transplant recipients aware of public statements and media reports relating to Silicon Valley Bank ("SVB"). The Company does not hold any cash at SVB nor does it have any banking relationship with SVB.

**Enquiries:**

**Verici Dx**

Sara Barrington, CEO  
Julian Baines, Chairman

[www.vericidx.com](http://www.vericidx.com)  
Via Walbrook PR

**Singer Capital Markets (Nominated Adviser & Broker)**

Aubrey Powell / Sam Butcher

**Tel: +44 20 7496 3000**

**Walbrook PR Limited**

Paul McManus / Stephanie Cuthbert /  
Sam Allen

**Tel: +44 20 7933 8780** or [vericidx@walbrookpr.com](mailto:vericidx@walbrookpr.com)  
**Mob: +44 7980 541 893 / +44 7796 794 663 /**  
**07502 558 258**

**About Verici Dx plc** [www.vericidx.com](http://www.vericidx.com)

Verici Dx is a developer of a complementary suite of leading-edge tests forming a kidney transplant platform for personalised patient and organ response risk to assist clinicians in medical management for improved patient outcomes. The underlying technology is based upon artificial intelligence assisted transcriptomic analysis to provide RNA signatures focused upon the immune response and other biological pathway signals critical for transplant prognosis of risk of injury, rejection and graft failure from pre-transplant to late stage. The Company also has a mission to accelerate the pace of innovation by research using the fully characterised data from the underlying technology and collaboration with medical device, biopharmaceutical and data science partners.

The foundational research was driven by a deep understanding of cell-mediated immunity and is enabled by access to expertly curated collaborative studies in highly informative cohorts in kidney transplant.

The two lead products are Clarava™, a pre-transplant prognosis test for the risk of early acute rejection, and Tutivia™, a post-transplant test focused upon acute cellular rejection, including sub-clinical rejection. These products seek to measure how a patient is likely to respond, and is responding, to a kidney transplant. These products are underpinned by extensive patented and published scientific research from the leading Mount Sinai Medical Center, for which the Company holds an exclusive worldwide licence.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [ms@seg.com](mailto:ms@seg.com) or visit [www.ms.com](http://www.ms.com).

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

STRGGGDXXGBDGXX